{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    20,
    25,
    26,
    34,
    41,
    45,
    47,
    48,
    49,
    50,
    52,
    54
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Schedule of Activities",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA)",
        "description": "Reference to the SoA table for data collection timing and frequency"
      },
      {
        "id": "ref_2",
        "name": "Dose Modifications",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.6",
        "sectionTitle": "Dose Modification",
        "description": "Reference for criteria regarding dose adjustments or discontinuation"
      },
      {
        "id": "ref_3",
        "name": "Adaptive Features",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 4",
        "sectionTitle": "Adaptive Protocol Features",
        "description": "Reference for limits and descriptions of adaptive study design features"
      },
      {
        "id": "ref_4",
        "name": "Exclusion Criteria",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2",
        "sectionTitle": "Exclusion Criteria",
        "description": "Cross-reference for blood donation restrictions"
      },
      {
        "id": "ref_5",
        "name": "Contraceptive Guidance",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.4",
        "sectionTitle": "Contraceptive Guidance and Collection of Pregnancy Information",
        "description": "Reference for appropriate contraceptive methods"
      },
      {
        "id": "ref_6",
        "name": "COVID-19 Risk",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.5",
        "sectionTitle": "COVID-19 Vaccine Risk Assessment",
        "description": "Reference for specific risks and mitigation measures due to COVID-19 vaccine"
      },
      {
        "id": "ref_7",
        "name": "Laboratory Tests",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference for the list of protocol-required safety laboratory assessments"
      },
      {
        "id": "ref_8",
        "name": "AE/SAE Procedures",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "Adverse Events: Definitions and Procedures",
        "description": "Reference for recording, evaluating, and reporting adverse events"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Procedures specific to screening sites (only in the US) detailed in Section 8",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "1.3 Schedule of Activities (SoA), Table 1",
        "pageNumber": 3
      },
      {
        "id": "annot_2",
        "text": "Acetaminophen should be limited to 1000 mg/day.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "5.3 Lifestyle Considerations (Table 5)",
        "pageNumber": 35
      },
      {
        "id": "annot_3",
        "text": "Herbal remedies must be discontinued at least 7 days prior to first admission until study completion.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "5.3 Lifestyle Considerations (Table 5)",
        "pageNumber": 35
      },
      {
        "id": "annot_4",
        "text": "Total molybdenum and PUF-molybdenum concentration-time profiles on Day 28 after the last 15 mg ALXN1840 dose will be extrapolated to Day 29 and subtracted from the observed Day 29 concentration-time profiles.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.4.4 Pharmacokinetic, Pharmacodynamic, and Biomarker Analyses",
        "pageNumber": 53
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "3.1 (US)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-03-18",
        "description": "Protocol Amendment 3.1 incorporating US-specific screening site procedures and alignment of zinc discontinuation timing.",
        "amendmentNumber": "3.1"
      },
      {
        "id": "ver_2",
        "versionNumber": "3.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-08-31",
        "description": "Amendment 3",
        "amendmentNumber": "3"
      },
      {
        "id": "ver_3",
        "versionNumber": "2.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-03-19",
        "description": "Amendment 2",
        "amendmentNumber": "2"
      },
      {
        "id": "ver_4",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-08-18",
        "description": "Amendment 1",
        "amendmentNumber": "1"
      },
      {
        "id": "ver_5",
        "versionNumber": "Original",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-05-12",
        "description": "Original Protocol",
        "amendmentNumber": "None"
      }
    ],
    "summary": {
      "referenceCount": 8,
      "annotationCount": 4,
      "versionCount": 5
    }
  }
}